Parties Agree That Mylan’s Pegfilgrastim Biosimilar Does Not Infringe Amgen’s Patent The Center for Biosimilars
Amgen, maker of the brand-name pegfilgrastim (Neulasta), and Mylan, which partnered with Biocon to develop a biosimilar (Fulphila), have entered a joint status …